Milestone Pharma raises $17 mln

Milestone Pharmaceuticals Inc. said Monday that it closed a $17 million series B financing led by Domain Associates. All of Milestone’s existing investors including Fonds de solidarité FTQ , Pappas Ventures, BDC Capital, GO Capital and iNovia Capital participated in the round. Montreal-based Milestone Pharma is a clinical stage cardiovascular company.

Milestone Pharmaceuticals picks up $17 mln

Canada-based Milestone Pharmaceuticals, a drug developer focused on cardiovascular diseases, has raised $17 million in Series B funding. Domain Associates led the round with participation from other investors that included Fonds de solidarité FTQ, Pappas Ventures, BDC Capital, GO Capital and iNovia Capital. In conjunction with the funding, Domain’s Debra Liebert has been added to Milestone’s board of directors.

127 Views

LeddarTech ropes in $7 mln

LeddarTech has raised $7 million in funding. BDC Capital and GO Capital led the round. Based in Quebec, LeddarTech provides advanced detection and ranging systems based on sensing technology.

Milestone Pharma Inks $13M

Milestone Pharmaceuticals Inc., a Montreal-based cardiovascular drug development company, has raised $13 million in fresh capital. Pappas Ventures, the Business Development Bank of Canada and GO Capital co-led the round. Fonds de solidarité FTQ, iNovia Healthcare Ventures and Fonds Bio-Innovation also participated. The money will be used for continued development. As a result of the round, Eric Linsley, managing partner of Pappas Ventures; Scott Weiner, senior principal at Pappas Ventures; and Dominic Jaikaran, principal at BDC Health Venture Fund, will join Milestone’s board.

PE HUB Community

Join the 12523 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget